Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bifurcation Stenting: The Next Generation

This article was originally published in Start Up

Executive Summary

The proper course of action for treating lesions at bifurcations remains controversial. In the face of numerous small studies with conflicting results and in the absence of large-scale studies investigating whether--or how--to stent the side branch of a bifurcation, cardiologists are searching for solutions. It's all very confusing, but one thing is becoming increasingly clear. Drug-eluting stents, which work so well in straight segments of vessels, aren't working in bifurcated vessels because bifurcations are distinct segments of anatomy, with particular shapes and unique flow characteristics. Start-ups have picked up on the fact that there is a $1 billion interventional cardiology market just waiting to be served with the right technology, and almost a dozen young companies have crowded into the field.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT037401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel